| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/29/2004 | US20040146574 Leukemic therapy; determination administering dosage |
| 07/29/2004 | US20040146573 Determining a therapeutic dosage of arsenic trioxide based upon the predetermined weight of the patient and administering; Leukemia; lymphomas; solid tumors; anticarcinoma and -tumor agents |
| 07/29/2004 | US20040146572 Determination of dosage bases on weight |
| 07/29/2004 | US20040146571 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 07/29/2004 | US20040146570 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 07/29/2004 | US20040146569 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 07/29/2004 | US20040146568 Antitumor agents; for solid tumors; administering cycles |
| 07/29/2004 | US20040146567 Mixture of silver supported inorganic compound with organonitrogen compound; storage stability; discoloration inhibition |
| 07/29/2004 | US20040146562 Depot formulations in the form of a suspension |
| 07/29/2004 | US20040146561 Useful in the healing of refractory fracture of elderly people and diabetic or osteoporosis patients; sustained release depot preparation, which, when applied locally, can release an active ingredient gradually |
| 07/29/2004 | US20040146555 Useful in the removal of abnormal keratinous material, as is to be observed, for example, in onychomycoses, psoriasis of the nail, or warts |
| 07/29/2004 | US20040146549 Amino acid sequences capable of facilitating penetration across a biological barrier |
| 07/29/2004 | US20040146547 Disposal system for transdermal dosage form |
| 07/29/2004 | US20040146542 Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal |
| 07/29/2004 | US20040146538 Pharmaceutical composition for oral use comprising an active principle liable to undergo a large first intestinal passage effect |
| 07/29/2004 | US20040146532 Agents and methods for treating pain |
| 07/29/2004 | US20040146508 Use of cd25 binding molecules in steroid-resistant patients |
| 07/29/2004 | US20040146503 Methods and compositions for inducing stable immune tolerance |
| 07/29/2004 | US20040146498 3-(2,3-Dihydroxycyclopentyl)-6-alkylthio-8-cyclopropylamino-3H-v-triazolo[4,5-d]pyrimidine derivatives as anticoagulants |
| 07/29/2004 | US20040146497 Wound healing agents and/or angiogenesis promoters; genetic engineering |
| 07/29/2004 | US20040146495 Analyzing a blood sample for secretin level |
| 07/29/2004 | US20040146494 Papaine containing pharmaceutical formulation resp its use |
| 07/29/2004 | US20040146482 Treatment of hair loss and skin aging |
| 07/29/2004 | US20040146477 Cosmetic or pharmaceutical agent |
| 07/29/2004 | US20040146470 Vitamin E and excipient |
| 07/29/2004 | US20040146469 Dermal penetration enhancers and drug delivery systems involving same |
| 07/29/2004 | US20040146468 With excipient; suppress or reduce the gustatory function, in particular as regards a bitter and/or sweet and/or acid taste |
| 07/29/2004 | US20040146459 Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use |
| 07/29/2004 | US20040146438 Method for recovery of metals from metal-containing materials using medium temperature pressure leaching |
| 07/29/2004 | DE10303670A1 New 14beta-alkyl-18-nor steroids useful as pharmaceuticals, e.g. for treating inflammation or tumors, or pharmaceutical intermediates |
| 07/29/2004 | DE10303668A1 New spiro(cyclopentano-perhydronaphthalene)-3,1'-alkanes useful as steroid mimetics potentially having steroidal activity and triterpenoid properties |
| 07/29/2004 | DE10303667A1 New 14-fluoro-15,17-dihydroxysteroid derivatives, useful for treating Alzheimer's disease and tumors, and as intermediates, are e.g. inhibitors of steroid dehydrogenase |
| 07/29/2004 | DE10301981A1 Use of combination of cinnarizin and dimenhydrinate to treat dizziness e.g. caused by inner ear disorders or violent motion |
| 07/29/2004 | DE10301930A1 Treatment and prevention of disease by combined enteral and parenteral administration, useful specifically for protection against poisoning by cholinesterase inhibitors |
| 07/29/2004 | DE10301917A1 Use of porphyrin precursors for photodynamic therapy of psoriasis and inflammatory skin and joint diseases |
| 07/29/2004 | DE10301851A1 Use of dialkylaminoalkylphenyl carbamate derivatives to protect humans from poisoning by cholinesterase inhibitors, including pesticides and chemical warfare agents |
| 07/29/2004 | DE10301300A1 Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein Use of acylated 4-amidino and 4-Guanidinobenzylaminen for the inhibition of plasma kallikrein |
| 07/29/2004 | DE10300902A1 Composition for treating viral infections, comprises tetracycline, and binds to host cell ribosomes, so prevents synthesis of proteins essential for virus replication |
| 07/29/2004 | DE10226592B4 Tumorhemmende Platin(II)-oxalato-Komplexe Antitumor platinum (II) complexes -oxalato |
| 07/29/2004 | CA2516398A1 Method of modulating il-6 |
| 07/29/2004 | CA2514879A1 Two or more enteric materials to regulate drug release |
| 07/29/2004 | CA2513399A1 Treatment of cancer with 2-deoxyglucose |
| 07/29/2004 | CA2513277A1 Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 07/29/2004 | CA2513219A1 Multivitamin regimen for renal patients |
| 07/29/2004 | CA2513133A1 Porphyrin derivatives |
| 07/29/2004 | CA2513132A1 New carboxylic acids and the esters thereof, pharmaceutical compositions containing these compounds and processes for the preparation thereof |
| 07/29/2004 | CA2513129A1 Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins |
| 07/29/2004 | CA2513042A1 Blood-brain barrier disruption inhibitor |
| 07/29/2004 | CA2512999A1 Use of 2-amino-2h-quinazoline derivatives for producing therapeutic agents |
| 07/29/2004 | CA2512983A1 Method of treating functional bowel disorders |
| 07/29/2004 | CA2512951A1 Carbohydrate conjugates to prevent abuse of controlled substances |
| 07/29/2004 | CA2512908A1 A method of treatment or prophylaxis of symptoms of herpes viral infection |
| 07/29/2004 | CA2512819A1 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells |
| 07/29/2004 | CA2512813A1 Use of substituted 2-phenylbenzimidazoles as phamaceutical compositions |
| 07/29/2004 | CA2512812A1 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| 07/29/2004 | CA2512765A1 Therapeutic agent for schizophrenia |
| 07/29/2004 | CA2512730A1 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 07/29/2004 | CA2512680A1 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 07/29/2004 | CA2512676A1 Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy |
| 07/29/2004 | CA2512672A1 Methods of treating lung diseases |
| 07/29/2004 | CA2512666A1 Combination therapy for anticoagulation |
| 07/29/2004 | CA2512602A1 Benzoxazole derivatives and their use as adenosine receptor ligands |
| 07/29/2004 | CA2512345A1 Odorless formulation for treating mucosal discontinuities |
| 07/29/2004 | CA2512320A1 Contact lens and eye drop rewetter compositions and their uses |
| 07/29/2004 | CA2512251A1 Ophthalmic compositions containing loratadine |
| 07/29/2004 | CA2512176A1 Anti-protozoal compositions comprising diclazuril |
| 07/29/2004 | CA2512022A1 Method of treating nausea, vomiting, retching or any combination thereof |
| 07/29/2004 | CA2512021A1 The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis |
| 07/29/2004 | CA2511682A1 Novel anticonvulsant derivative salts |
| 07/29/2004 | CA2511659A1 Methods for reducing mortality associated with acute myocardial infarction |
| 07/29/2004 | CA2510400A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 07/29/2004 | CA2509251A1 Method of treating cognitive decline due to sleep deprivation and stress |
| 07/29/2004 | CA2507948A1 Aminoindazole derivates and use thereof as kinase inhibitors |
| 07/29/2004 | CA2507945A1 Prevention and treatment of alzheimer's disease |
| 07/28/2004 | EP1441034A1 Methods of evaluating phosphatase inhibitors |
| 07/28/2004 | EP1440976A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| 07/28/2004 | EP1440973A2 Epothilone derivatives, preparation and use |
| 07/28/2004 | EP1440972A1 Novel benzothiepines having pharmaceutical activity. |
| 07/28/2004 | EP1440965A1 Antimicrobial compounds |
| 07/28/2004 | EP1440962A1 Stabilized compositions of aqueous reduced coenzyme q solution |
| 07/28/2004 | EP1440709A2 Combinations comprising cGMP PDE5 inhibitors. |
| 07/28/2004 | EP1440701A1 Method of coating medical devices |
| 07/28/2004 | EP1440691A2 Treatment of neurotic disorders |
| 07/28/2004 | EP1440690A2 Treatment of neurotic disorders |
| 07/28/2004 | EP1440689A2 Treatment of neurotic disorders |
| 07/28/2004 | EP1440688A1 Peroxisome proliferator activated receptor ligands and process for producing the same |
| 07/28/2004 | EP1440687A1 Antiradicals and fat compositions, foods, drinks, drugs or feeds containing the antiradicals |
| 07/28/2004 | EP1440686A1 Aerosol compositions |
| 07/28/2004 | EP1440682A1 Composition in the form of an emulsion that can be used to treat plantar bromhidrosis and/or hyperhidrosis |
| 07/28/2004 | EP1440619A1 Fat based food products comprising sterols |
| 07/28/2004 | EP1440169A1 Methods and compositions for the treatment and diagnosis of pain disorders using 57749 |
| 07/28/2004 | EP1440166A2 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777 |
| 07/28/2004 | EP1440165A2 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 07/28/2004 | EP1440114A1 Material consisting of at least a biodegradable polymer and cyclodextrins |
| 07/28/2004 | EP1440091A1 Nogo receptor homologues and their use |
| 07/28/2004 | EP1440079A1 Acyclic linker-containing oligonucleotides and uses thereof |
| 07/28/2004 | EP1440077A1 Synthetic heparin pentasaccharides |
| 07/28/2004 | EP1440076A1 Silicon compounds |
| 07/28/2004 | EP1440075A1 Novel 3beta-amino azabicyclooctane heteroaromatic amide derivatives, preparation method and therapeutic uses thereof |
| 07/28/2004 | EP1440073A1 Pde9 inhibitors for treating cardiovascular disorders |